Why the study?
Do dabigatran and rivaroxaban prevent stroke without excessive bleeding in patients undergoing electrical cardioversion for atrial fibrillation?
Do dabigatran and rivaroxaban prevent stroke without excessive bleeding in patients undergoing electrical cardioversion for atrial fibrillation?
Dabigatran and rivaroxaban appear safe and effective for stroke prevention in patients undergoing elective electrical cardioversion for non-valvular atrial fibrillation in routine clinical practice.
Answers are grounded in this paper and cite their sources.
May inform periprocedural NOAC use in cardioversion; hypothesis-generating and requires randomized confirmation.
Patients scheduled for atrial fibrillation (AF) cardioversion were excluded from clinical trials of novel oral anticoagulants (NOACs). We evaluated efficacy and safety of NOACs in patients undergoing electrical cardioversion for AF. We performed a monocentric study of all patients on NOACs who underwent elective electrical cardioversion for non-valvular AF between January 2012 and December 2014. We analyzed incidence of stroke and bleeding at 30 days. Fifty patients were included, 28 receiving dabigatran, 22 rivaroxaban. Mean age was 65 ± 12 years. Mean CHADS2-VA2SC and HASBLED scores were 3 ± 1.8 and 2.2 ± 1.1 respectively. Transoesophageal echocardiography was performed in 41 (79%) patients, revealing a thrombus in 2 (5%). No clinical evidence of stroke occurred in the 30 days, 1 major gastrointestinal bleeding (2%) in patient on rivaroxaban (led to premature discontinuation) and 3 minor bleedings. NOACs seem to be safe in daily practice of electrical cardioversion in our population.
No takes yet. Share an insight, caveat, or question.
Coquard et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: